[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acetylcysteine-adverse-reaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acetylcysteine-adverse-reaction":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100604997",false,"NCT07156786","N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial","N-Acetylcysteine Role on Urinary KIM-1 and Serum Creatinine Level in Cancer Patient With Cisplatin Based Chemotherapy","Inclusion Criteria:\n\n* Patient with cancer\u002F malignancy proven by histopathological examination\n* Patient with GFR ≥60 ml\u002Fmins\u002F1,73 m²\n* Patient with normal complete blood count and liver function test result\n* Patient with good performance status (Karnofsky score ≥80)\n* Patients with cisplatin based chemotherapy\n\nExclusion Criteria:\n\n* Patient that can not tolerate N-Acetylcysteine usage\n* Patient with history of hypersensitivity to N-Acetylcysteine\n* Patient that given other potentially nephrotoxic drug, such as furosemide, non-steroidal anti-infammatory drugs, aminoglycosides, amphotericin B, cephalosporine\n* Patient that given other chemotherapy drug, such as permetrexed, ifosfamide, gemcitabin, bevacizumab, cetuxsimab\n* Patient with history of malignant or uncontrolled hypertension\n* patient with congestive heart failure, kidney structure abnormality, and acute infection\n* Pregnant or lactating women\n* Patient refusing to participate in the research","ALL","18 Years",{"count":18,"type":19},72,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","The goal of this clinical trial is to learn if N-Acetylcysteine drug works to protect kidney function in adults patient with cancer. Kidney function will be measured by laboratory parameter using urine sample (KIM-1 urine) and blood sample (serum creatinine). The main questions it aims to answer are:\n\n1. Does N-Acetylcysteine lower the level of KIM-1 (Kidney Injury Molecule) in patients urine indicating kidney function protection?\n2. Does N-Acetylcysteine lower the level of creatinine in patients blood indicating kidney function protection?\n\nParticipants will:\n\n1. Had their blood and urine sample taken before taking the drugs (N-Acetylcysteine or placebo)\n2. Underwent cisplatin based chemotherapy\n3. Taken placebo or N-Acetylcysteine for seven days (1 day before chemotherapy, on the chemotherapy day, and 5 days after chemotherapy)\n4. Had their blood and urine sample taken twice after taking the drugs (1 week and 3 weeks after chemotherapy)\n5. Had their symptoms monitor during and after taking the drugs. Every possible side effect, hospitalization, or death will be recorded.",[26,27,28,29,30],"Kidney Function Issue","Acute Kidney Injury","Cancer (Solid Tumors)","Kidney Function Tests","Acetylcysteine Adverse Reaction",[32,33,34,35],"kidney injury molecule 1","KIM-1","Creatinine","N-Acetylcysteine","NOT_YET_RECRUITING","2025-09-13",{"date":39,"type":40},"2025-09-19","ACTUAL",{"date":42,"type":19},"2025-09-15",{"date":44,"type":19},"2027-08-31",{"name":46,"class":47},"Fakultas Kedokteran Universitas Indonesia","OTHER",""]